Articles tagged "B cells"

2018 American Transplant Congress
Designing Novel Selective Immunoproteasome Inhibitors Reveals a Critical Role of the Immunoproteasome in Protecting Antibody Secreting B Cells from Apoptosis
J. Assaker,¹ N. Murakami,¹ S. Eskandari,¹ M. Uehara,¹ C. Nathan,² H. Li,³ G. Lin,² J. Azzi.¹
¹Transplantation Renal Center, Harvard Medical School, Boston; ²Microbiology and Immunology, Weill Cornell Medicine, New York; ³Cryo-EM Structural Biology Laboratory, Van Andel Research Institute, Grand Rapids.
Constitutive proteasomes (c-20S) are ubiquitously-expressed cellular proteases that degrade polyubiquitinated proteins and regulate cell functions. Its inhibitor, bortezomib, is a plasma cell-targeted therapy used in…
2018 American Transplant Congress
Alloreactive B Cells Acquire Cell-Intrinsic Hyporesponsiveness in Tolerant Recipients
S. Khiew,¹ D. Jain,¹ J. Young,¹ J. Chen,¹ J. Yang,¹ Q. Wang,¹ D. Yin,¹ R. Sciammas,² A. Chong.¹
¹Department of Surgery, The University of Chicago, Chicago, IL; ²Comparative Medicine, University of California, Davis, CA.
Donor-specific transplantation tolerance has long been an aspiration of clinical transplantation. Recently, we have reported that multiple mechanisms are required to reinforce profound hyporesponsiveness of…
2018 American Transplant Congress
The Regulatory Role of Plasma Cells (as Bregs) is Counterbalanced by a NOVEL Inflammatory Role in Murine Transplant and Autoimmune Models
Z. Song,^1,2 Y. Zhou,² Q. Ding,¹ D. Rothstein.¹
¹Thomas E. Starzl Transplantation Institute, University of Pittsburgh, Pittsburgh; ²School of Medicine, Tsinghua University, Beijing, China.
Plasma Cells (PCs; B220lowCD138hiBlimp1+Ig+) in LN and spleen were shown to be the major source of B cell lineage IL-10, and absence of PCs worsens…
2018 American Transplant Congress
Preemptive B Cell Depletion Modulates Pathogenic Alloimmunity Associated with Selective Non-Activating CD28 Blockade
N. O'Neill,¹ T. Zhang,¹ W. Sun,¹ G. Braileanu,¹ X. Cheng,¹ I. Tatarov,¹ W. Hassanein,¹ Z. Habibabady,¹ B. Cerel,¹ K. Reimann,² A. Azimzadeh,¹ R. Pierson.¹
¹Surgery, University of Maryland School of Medicine, Baltimore, MD; ²University of Massachusetts Medical School, Boston, MA.
Purpose: Because anti-donor alloantibody (alloAb) elaboration is associated with chronic allograft rejection, peri-transplant B cell depletion is being explored to modulate pathogenic alloimmunity. Here, we…
2018 American Transplant Congress
The Impact of Rituximab Dose on Hepatitis B Virus Reactivation in HBsAg-Negative/anti-HBc-Positive Kidney Transplant Recipients
J. Lee,¹ J. Park,² Y. Jung,¹ D. Kim,¹ J. Lee,¹ S. Song,³ J. Lee,⁴ J. Lee,¹ B. Kim,⁵ M. Kim,¹ S. Kim,¹ Y. Kim,¹ K. Huh.¹
¹Surgery, Yonsei University College of Medicine, Seoul, Korea; ²Internal Medicine (Gastroenterology), Yonsei University College of Medicine, Seoul, Korea; ³Surgery, Ewha Womans University, School of Medicine, Seoul, Korea; ⁴Surgery, CHA Bundang Medical Center, CHA University, Seongnam, Korea; ⁵Internal Medicine (Nephrology), Yonsei University College of Medicine, Seoul, Korea.
Background: Hepatitis B virus (HBV) reactivation is well-recognized complication of rituximab. Although use of rituximab for sensitized patients continues to increase in kidney transplantation, the…
2018 American Transplant Congress
CFZ533, a New Anti-CD40 mAB Demonstrates Comparable Efficacy and Better Renal Function versus Tacrolimus in De-Novo CNI-Free Kidney Transplantation
B. Nashan,¹ H. Tedesco,¹ M. van den Hoogen,¹ S. Berger,¹ D. Cibrik,¹ S. Mulgaonkar,¹ D. Leeser,¹ R. Alloway,¹ A. Patel,¹ J. Pratschke,¹ C. Sommerer,¹ A. Wiseman,¹ A. van Zuilen,¹ U. Laessing,² J. Rush,² B. Haraldsson,² O. Witzke.¹
¹CFZ533 Study Group, Basel, Switzerland; ²Novartis Pharma, Basel, Switzerland.
Purpose: To assess the potential of CFZ533 as primary immunosuppressant in a calcineurin(CNI)-free regimen in de novo kidney transplant (KTx) patients(pts).Method: CFZ533 is a new,…
2018 American Transplant Congress
Immunomodulation of Alloantibody Responses
C. Schuetz, M. Climov, A. Paril, Z. Wang, A. Andrews Roy, N. Navarro Alvarez, A. Matar, D. Sachs, R. Duran-Struuck, C. Huang.
Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA.
We have shown that i.v. exposure to MHC-mismatched donor PBMC using a novel, mild conditioning protocol results in B-cell tolerance with transient T-cell unresponsiveness. Here…
2018 American Transplant Congress
CD8-Expressing Transitional B Cells Dominate B Cell Reconstitution in Transplanted Monkeys Receiving Mixed Chimerism Conditioning
K. Pruner, J. Paster, S. Wiebke, O. Jane, H. Isabel, D. Abbas, B. Gilles, M. Joren.
Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA.
IntroductionTolerance of heart or lung allografts have been achieved for the first time in nonhuman primates (NHPs) using a mixed chimerism conditioning regimen. However, the…
2017 American Transplant Congress
A Prospective Iterative Trial of Carfizomib-Based Desensitization Trial: Initial Comparative Observations.
S. Tremblay,¹ A. Shields,^1,2 R. Alloway,¹ P. Brailey,¹ A. Leino,¹ A. Lichvar,¹ B. Abu Jawdeh,¹ J. Driscoll,¹ A. Girnita,¹ E. Woodle.¹
¹U of Cincinnati, Cincinnati; ²Christ Hospital, Cincinnati
Carfilzomib (CFZ) is a 2nd generation proteasome inhibitor different form bortezomib in that it irreversibly disables 20s and 26s proteasomes.Results from the first 2 phases…
2017 American Transplant Congress
IgM Immunotherapy Restores Immune Homeostasis in Type 1 Diabetes.
P. Chhabra,¹ C. Wilson,² D. Moore,² K. Brayman.¹
¹Surgery, University of Virginia, Charlottesville, VA; ²Pediatric Endocrinology, Vanderbilt University, Nashville, TN
Goal: To determine the mechanism(s) by which IgM immunotherapy restores immune homeostasis in Type 1 Diabetes (T1D).Background: IgM immunotherapy prevents the onset and progression of…